Impact of Inhaled Corticosteroids on Acute Asthma Hospitalization in Sweden 1978 to 1991

Medical Care

Volumn 34, Issue 12, 1996, Pages 1188-1198

  Gerdtham, Ulf G ^a   Hertzman, Peter ^b   Jönsson, Bengt ^a   Boman, Gunnar ^c  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bronchial asthma; Costs; Drugs; Hospitalization; Inhaled corticosteroids; Panel data; Pooled cross section time series analysis

Indexed keywords

CORTICOSTEROID;

AGED; ARTICLE; ASTHMA; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; ECONOMICS; HOSPITALIZATION; HUMAN; INFANT; INHALATIONAL DRUG ADMINISTRATION; PRESCHOOL CHILD; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; SWEDEN;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ASTHMA; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; HOSPITALIZATION; HUMANS; INFANT; MODELS, STATISTICAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SWEDEN;

EID: 0030345339     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199612000-00004     Document Type: Article

References (32)

1. Barnes PJ. A new approach to the treatment of asthma. N Engl J Med 1989;321:1517.
2. Boman G. Epidemiology of obstructive lung disease in the Nordic countries. Eur Respir Rev 1991;1:316.
3. Åberg N. Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989;19:59.
4. Weiss KB, Sullivan SD. The economic costs of asthma: A review and conceptual model. Pharmacoeconomics 1993;4:14.
5. Weiss KB, Gergen P, Hodgson T. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862.
6. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Rockville, MD: National Institutes of Health, National Heart, Lung and Blood Institute, 1995. Publication no. 95-3659.
7. British Thoracic Society. Guidelines on the management of asthma. Thorax 1993;48(suppl 2):1.
8. Brogden R, McTavish D. Budesonide. An updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375.
9. Selroos O. The effects of inhaled corticosteroids on the natural history of obstructive lung diseases. Eur Respir Rev 1991;1:354.
10. Ädelroth E, Thompson S. Advantages of high-dose inhaled budesonide. Lancet 1988;ii:476.
11. Otulana BA, Varma N, Bullock A, Higenbottom T. High dose nebulized steroid in the treatment of chronic steroid-dependent asthma. Respir Med 1992;86:105.
12. Karalus NC, Harrison AC. Inhaled high-dose beclomethasone in chronic asthma. N Z Med J 1987;100:305.
13. 2-agonist controversy: Observations, explanations and relationship to asthma epidemiology. Drug Safety 1994;11:259.
14. National Board of Health and Welfare. In-patient care register. Stockholm: National Board of Health and Welfare, 1978-1983, 1985-1991.
15. Nilsson AC, Spetz CL, Carsjö K, Nightingale R, Smedby B. The validity of the inpatient care register: The information about diagnoses is better than its reputation (in Swedish). Läkartidningen 1994;91:598.
16. National Corporation of Swedish Pharmacies. Sales statistics. Stockholm: National Corporation of Swedish Pharmacies, 1978-1983, 1985-1991.
17. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for DDD. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 1993.
18. Wessling A. The national prescription survey. A database for drug utilization studies in Sweden: Results and experiences from the 1970s and the 1980s. Huddinge: Department of Clinical Pharmacology of the Karolinska Institute, Huddinge University Hospital, 1990. Thesis.
19. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 1993.
20. Gerdtham U-G, Hertzman P, Boman G, Jönsson B. Impact of inhaled corticosteroids on asthma hospitalization in Sweden: A pooled regression analysis. Stockholm: Stockholm School of Economics, 1993. EFI Research Report Nr 91.
21. Greene WH. Econometric analysis. New York, NY: MacMillan Publishing Company, 1990.
22. Burney P, Papacosta A, Whitey J, Colley J, Holland W. Hospital admission rates and the prevalence of asthma symptoms in 20 local authority districts. Thorax 1991;46:574.
23. Larsson L, Boethius G, Uddenfeldt M. Differences in utilization of asthma drugs between two neighboring Swedish provinces, relation to prevalence of obstructive airway disease. Thorax 1994;49:41.
24. Hay I, Higenbottom TW. Has the management of asthma improved? Lancet 1987;2:609.
25. Fisher ES, Wennberg JE, Stukel TA, Sharp SM. Hospital readmission rates for cohorts of medicare beneficiaries in Boston and New Haven. N Engl J Med 1994;331:989.
26. Greene WH. User's manual and reference guide. Version 6.0. Australia: Econometric Software Inc, 1991.
27. Federation of County Councils. Cost per discharge, bed-days, outpatient visit, 1991 (in Swedish). Stockholm: Federation of County Councils, 1993.
28. Jönsson B, Carlsson P. The effects of cimetidine on the cost of ulcer disease in Sweden. Soc Sci Med 1991;33:275.
29. Bolton MB, Tilley BC, Kuder J, Reeves T, Schultz LR. The costs and effectiveness of an education program for adults who have asthma. J Gen Intern Med 1991;6:401.
30. Läkemedelsstatistik AB. Medical Index Sweden. Stockholm: Läkemedelsstatistik AB, 1991.
31. Rutten-van Mölken M, Van Doorslaer E, Jansen M, Van Essen-Zandvliet E, Rutten F. Cost-effectiveness of inhaled corticosteroids plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics 1993;4:257.
32. Perera BJC. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country. Arch Dis in Childhood 1995;72:312.